Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility by Cauffiez Christelle, Lo-Guidice Jean-Marc, Quaranta Sylvie, Allorge Delphine, Chevalier Dany, Cenée Sylvie, Hamdan Rima, Lhermitte Michel, Lafitte Jean-Jacques, Libersa Christian, Colombel Jean-Frédéric, Stücker Isabelle, Broly Franck in Biochemical and biophysical research communications (2004). PubMed


The human cytochrome CYP2A13, which is mainly expressed in the respiratory tract, has been shown to be highly efficient in vitro in the metabolism of tobacco-smoke carcinogens and procarcinogens such as 4-methylnitroso-1-(3-pyridyl)-1-butanone (NNK). In order to investigate the extent of CYP2A13 genetic polymorphism in a French Caucasian population of 102 individuals, a screening for sequence variations in the 5'-untranslated and protein encoding regions of its gene was performed using a polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) strategy. Six polymorphisms in the coding region were identified, including two rare missense mutations (C474G or Asp158Glu, G967T or Val323Leu) and one nonsense mutation (Arg101Stop). This deleterious mutation, the most frequent (5%) in our population, presumably encodes a severely truncated protein. The influence of the nonsense mutation in lung cancer susceptibility was examined by PCR-SSCP using peripheral blood DNA from 204 cases of lung cancer and 201 controls. The CYP2A13*7 allele, which harbours the C301T mutation, was present in 2.0% of controls and 3.4% of cases. However, multivariate analysis showed an elevated risk for small cell lung cancer in subjects heterozygous for the null allele (odds ratio OR=9.9; 95% confidence interval CI=1.9-52.2). This increased risk was not linked to other histological types of lung cancer.

[ hide abstract ]

Discussed In Paper


Dosing Information

No dosing information annotated.